Omnipod® 5 | Discussion Guide | Medicare





Pod shown without the necessary adhesive

Talk to your doctor about Omnipod 5 and Medicare Part D

Omnipod 5 is the #1 most prescribed Automated Insulin Delivery system through Medicare Part D.*

Tired of daily insulin injections? Omnipod 5 is a small, tube-free and waterproof[†] Pod that communicates with your CGM/Sensor to automatically adjust insulin delivery based on your insulin needs and sensor trends.

Bring or send this to your Doctor to kickstart a conversation on how Omnipod 5 may simplify your life.

Questions	Why Omnipod 5
☐ Does Omnipod 5 have broad Medicare coverage?	Yes, Omnipod 5 has broad coverage under Medicare Part D [‡] To check your coverage and find out what your copay might be, call our Omnipod Medicare Specialists at: 1-800-591-9948.
☐ Will Omnipod 5 help protect against highs and lows?	Connected to your CGM/Sensor, Omnipod 5 automatically adjusts by increasing, decreasing or pausing insulin delivery every 5 minutes to help protect against highs and lows, day and night. ¹⁻³
☐ Who can use Omnipod 5?	Omnipod 5 is cleared for people with type 1 diabetes, aged 2+ and people with type 2 diabetes, aged 18+.
☐ What CGM does Omnipod 5 work with?	Omnipod 5 currently integrates with Dexcom G6, Dexcom G7 and the FreeStyle Libre 2 Plus Sensor. Sensors are sold separately and require a separate prescription.
Can I control Omnipod 5 with a smartphone?	You can take full control of the Pod from the Omnipod 5 app on your compatible Android and iPhone smartphone! Additionally, you can also use the free Controller, included with your first prescription of Omnipod 5.

Still have questions?

Our Omnipod Specialists are here to help. Call them today at 1-800-591-9948.

- * Insulet US Data on file, Jan. 2024 Mar. 2025 (IQVIA).
- [†] The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof. The Dexcom G6 sensor and transmitter are water-resistant and may be submerged under eight feet of water for up to 24 hours without failure when properly installed. The Dexcom G7 sensor is water-resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes.
- [‡] Insulet US Data on file, Feb. 2024 Jan. 2025 (IQVIA)
- § For a list of compatible smartphone devices visit omnipod.com/compatibility
- 1. Brown et al. Diabetes Care (2021). Study in 240 people with T1D aged 6 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average overnight time (12AM-6AM) with high blood glucose in adults/adolescents and children for standard therapy vs. Omnipod 5 = 32.6% vs. 26.7%; 42.2% vs. 20.7%. Average day time (6AM-12AM) with high blood glucose in adults/adolescents and children for standard therapy vs. Omnipod 5 = 32.6% vs. 26.1%; 46.4% vs. 33.4%. Average overnight time (12AM-6AM) with low blood glucose in adults/adolescents and children for standard therapy vs. Omnipod 5 = 3.6% vs. 1.2%; 2.5% vs. 1.2%; 2.5% vs. 1.2%. Average day time (6AM-12AM) with low blood glucose in adults/adolescents and children for standard therapy vs. Omnipod 5 = 2.6% vs. 1.4%; 2.1% vs. 2.0%.
- 2. Sherr J, et al. Diabetes Care (2022). Study in 80 children with T1D aged 2 to 5.9 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average overnight time (12AM-6AM) with high blood glucose in children for standard therapy vs. Omnipod 5 = 38.4% vs. 16.9%. Average day time (6AM-12AM) with high blood glucose in children for standard therapy vs. Omnipod 5 = 39.7% vs. 33.7%. Average overnight time (12AM-6AM) with low blood glucose in children for standard therapy vs. Omnipod 5 = 3.4% vs. 2.1%. Average day time (6AM-12AM) with low blood glucose in children for standard therapy vs. Omnipod 5 = 3.4% vs. 2.6%.
- 3. Pasquel FJ, et al. JAMA Network Open (2025). Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. Mean overnight time >180 mg/dL (12AM-6AM) as measured by CGM: ST = 55%, 3-mo Omnipod 5 = 36%. Mean overnight time in <70 mg/dL (12AM-6AM) as measured by CGM: ST = 0.10%, 3-mo Omnipod 5 = 0.22%. Mean daytime <70 mg/dL (6AM-12AM) as measured by CGM: ST = 0.16%, 3-mo Omnipod 5 = 0.17%. Statistical testing not done to assess significance of change between ST phase and Omnipod 5 system phase.

Helpful info for your Doctor

SIMPLE TO ACCESS

Give your patients a simple way to try, start, and stay on Omnipod[®] 5.



Covered under Medicare Part D

Omnipod 5 is the only tube-free AID system covered under Medicare part D without a C-peptide test



Simple pharmacy access
Patients can get Pods when
they pick up their insulin





INSTRUCTIONS FOR PRESCRIBING OMNIPOD 5 WITH PATIENTS' PREFERRED SENSORS:

Insulet • 100 Nagog Park, Acton, MA 01720 • 1-800-591-3455 • omnipod.com

The Omnipod 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 2 years of age and older and type 2 diabetes mellitus in persons 18 years of age and older. The Omnipod 5 System is intended for single patient, home use and requires a prescription. The Omnipod 5 System is compatible with the following U-100 insulins: NovoLog®, Humalog®, and Admelog®.

Refer to the Omnipod 5 Automated Insulin Delivery System User Guide and www.omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions. Warning: DO NOT start to use the Omnipod 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia. Warning: Do not use SmartAdjust technology for people under the age of 2 or who require less than 5U of insulin per day.

©2025 Insulet Corporation. Omnipod, the Omnipod logo, the Omnipod 5 logo, Simplify Life and SmartAdjust are trademarks or registered trademarks of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. Dexcom Dexcom Go, and Dexcom G7 are registered or unregistered trademarks of Dexcom, Inc. in the United States and/or other countries and are used with permission. All other trademarks are the property of their respective owners. The use of third party trademarks does not constitute an endorsement or imply a relationship or other affiliation. INS-0HS-07-2025-00273 v2.0

